Malaria drug treatment breakthrough

An international study, involving researchers from Griffith University's Eskitis Institute, has discovered a molecule which could form the basis of powerful new anti-malaria drugs.

Professor Vicky Avery from Griffith University's Eskitis Institute is co-author of the paper "Quinolone-3-Diarylethers: a new class of drugs for a new era of " which has been published in the journal Science Translational Medicine.

"The 4(1H)-quinolone-3- diarylethers are selective of the parasite mitochondrial cytochrome bc1 complex," Professor Avery said.

"These compounds are highly active against the types of malaria parasites which infect humans, Plasmodium falciparum and Plasmodium vivax," she said.

"What is really exciting about this study is that a new class of drugs based on the 4(1H)- quinolone-3- diarylethers would target the at different stages of its lifecycle."

This provides the potential to not only kill the parasite in people who are infected, thus treating the clinical symptoms of the disease, but also to reduce .

"Just one of these properties would be of great benefit but to achieve both would really make a difference in reducing the disease burden on developing nations," Professor Avery said.

"There is also the real possibility that we could begin to impact on the incidence and spread of malaria, bringing us closer to the ultimate goal of wiping out malaria altogether."

The selected preclinical candidate compound, ELQ-300, has been demonstrated to be very effective at blocking transmission in the mouse models.

There is a further benefit in that the predicted dosage in patients would be very low and it's expected that ELQ-300, which has a long half-life, would provide significant protection.

The development of a new chemical class of anti-malarial drugs is very timely as the parasite is becoming increasing resistant to currently available treatments.

Eskitis Director Professor Ronald J Quinn AM said "I congratulate Professor Avery on her contribution to the discovery of this new class of anti-malarials.

"This is an exciting discovery that closely aligns with the Institute's focus on global health and fighting diseases that burden the developing world. We are continuing to take the fight to along a number of fronts, including targeting its many life cycle stages."

Related Stories

New discovery could lead to powerful new anti-malaria drugs

Mar 20, 2013

An international study has discovered a molecule which could form the basis of powerful new anti-malaria drugs. The paper "Quinolone-3-Diarylethers: a new class of drugs for a new era of malaria eradication" has been published ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

17 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments